Journal article
A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND)
H Ma, MW Parsons, S Christensen, BCV Campbell, L Churilov, A Connelly, B Yan, C Bladin, T Phan, AP Barber, S Read, GJ Hankey, R Markus, T Wijeratne, R Grimley, N Mahant, T Kleinig, J Sturm, A Lee, D Blacker Show all
International Journal of Stroke | Published : 2012
Abstract
Background and hypothesis: Thrombolytic therapy with tissue plasminogen activator is effective for acute ischaemic stroke within 4·5h of onset. Patients who wake up with stroke are generally ineligible for stroke thrombolysis. We hypothesized that ischaemic stroke patients with significant penumbral mismatch on either magnetic resonance imaging or computer tomography at three- (or 4·5 depending on local guidelines) to nine-hours from stroke onset, or patients with wake-up stroke within nine-hours from midpoint of sleep duration, would have improved clinical outcomes when given tissue plasminogen activator compared to placebo. Study design: EXtending the time for Thrombolysis in Emergency Neu..
View full abstractGrants
Funding Acknowledgements
EXTEND is supported in part by Commonwealth Scientific and Industrial Research Organisation (CSIRO) of Australia through the CSIRO Preventative Health Flagship Cluster as part of the START-EXTEND Collaborative Study with funding from the CSIRO National Research Flagship Collaboration Fund.The FNI acknowledges the strong support from the Victorian Government and, in particular, the funding from the Operational Infrastructure Support Grant. In addition, we like to acknowledge the help in the preparation of this manuscript from the EXTEND study manager Ms Sue Bates and study coordinator Ms Elise Cowley.